Company Profile
Aptose Biosciences, Inc. Stock Price, News & Analysis
- Ticker:
- APTO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada and listed in the U
Why the stock is moving
Current closing-price context is not available for APTO.
Company overview
Precision Hematology Company
Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia.
Tuspetinib Triplet
The TUSCANY study evaluates tuspetinib with venetoclax and azacitidine as a frontline regimen for newly diagnosed AML patients who are ineligible for intensive induction chemotherapy.
Mutation-Agnostic Strategy
The triplet is intended to provide activity across a genetically diverse AML population without adding overlapping toxicities to the standard venetoclax and azacitidine backbone.
Future catalysts
Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.
Recent news
- 01
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
Source: Aptose Biosciences, Inc.
- 02
- 03
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
Source: Aptose Biosciences, Inc.
- 04
Aptose Reports First Quarter 2026 Results
Source: Aptose Biosciences, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Aptose Biosciences, Inc. do?
Precision Hematology Company Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia. Tuspetinib Triplet The TUSCANY study evaluates tuspetinib with venetoclax and azacitidine as a frontline regimen for newly diagnosed AML patients who are ineligible for intensive induction...
On which exchange is APTO stock listed?
Aptose Biosciences, Inc. (APTO) is associated with NASDAQ, Canada and listed in the U, Biopharma.
What is tuspetinib?
Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.
Which conditions is Aptose Biosciences, Inc. targeting with tuspetinib?
Aptose Biosciences, Inc. is associated with oncology, hematology, genetic disease based on its company overview and current catalyst commentary.
How does Aptose Biosciences, Inc. describe recent progress with tuspetinib?
Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.
What is Precision?
Precision Hematology Company Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia.
What should investors watch for with Precision?
Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.
What is Hematology?
Precision Hematology Company Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia.